Radioligands: Live Session From The Uromigos Live & Unplugged 2024
By Brian Rini, MD, FASCO, Michael Morris, MD, Tanya Dorff, MD, Karen Autio, MD - Last Updated: October 3, 2024The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment. Panel moderator Brian Rini, MD, was joined by Michael Morris, MD; Tanya Dorff, MD; Karen Autio, MD; and Gary T. Smith, MD, for this informative and compelling discussion.
Advertisement
Click the image below to access the slide PDFs.
Advertisement
Related Posts
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.